



## Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

December 3, 2025

*Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer*

*Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS)*

LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagnostics and new research on breast cancer diagnostics at upcoming scientific meetings.

At the 2025 [North American Conference on Lung Cancer](#) (NACLC), December 5 - 7, in Chicago, IL, Biodesix will present new findings on its on-market Nodify Lung® tests, with data that spotlight the importance of timely, accurate lung nodule risk classification to support the early detection of lung cancer:

- **Refining Post-test Probability of Lung Cancer Using Post-Market Data from a Blood-based Biomarker Test in Pulmonary Nodule Patients.**

Authors: Michael N. Kammer, PhD (*Biodesix Head of Radiomics and Presenter*); Trevor Pitcher, PhD; Gary Pestano, PhD; Laura Peek, PhD; James R. Jett, MD, MS, FCCP; Steven C. Springmeyer, MD, FCCP.

- **Modeling the Impact of an Autoantibody Blood Test for Lung Cancer on Time to Diagnosis in Pulmonary Nodule Assessment: A Multi-Cohort Analysis.**

Authors: Kathryn Long, MD (*Presenter*); Gerard A. Silvestri, MD, MS, Master FCCP; Michael N. Kammer, PhD; Trevor Pitcher, PhD; James Jett, MD; Viswam S. Nair, MD.

The company will also present data on the development of a new ultra-sensitive ESR1 test for initial detection and monitoring of the mutations in HR+/HER2- advanced breast cancers at the [San Antonio Breast Cancer Symposium](#), December 9 -12, San Antonio, TX. This innovative test is now available to biopharmaceutical customers as part of the company's [Development Services](#) offering:

- Poster Session 4, PS4-02-29: [Development of an ultra-sensitive droplet digital PCR test for monitoring ESR1 variants in liquid biopsies](#).

Authors: Leisa Jackson (*Biodesix Staff Scientist and Presenter*), Helen Halpin, and Gary Pestano, PhD.

In addition, at the recent International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025 Meeting in November, Biodesix was awarded two distinguished recognitions: a Best General Poster Research Presentation and a Top 5% Research Certificate. The presented research highlighted the significant healthcare costs associated with pulmonary nodules and the widespread lack of appropriate follow-up. These gaps in nodule surveillance contribute to delayed diagnoses and increased downstream clinical and economic burden. ISPOR will publish all award-winning research in their December 2025 conference supplement issue of *Value in Health*.

- [PT5: Pulmonary Nodule \(PN\)-Related and Lung Cancer-Related Workup Costs Within the Two-Year Period After Diagnosis of a PN in the United States](#)

Author: Kimberly Le, MBA, MS, PharmD (*Biodesix Director of HEOR and Presenter*).

### About Biodesix:

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. **Biodesix Diagnostic Tests**, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. **Biodesix Development Services** enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit [biodesix.com](#).

### Biodesix Contacts:

#### Media:

Natalie St. Denis, Director Corporate Communications, Biodesix  
natalie.stdenis@biodesix.com  
(720) 925-9285

#### Investors:

Chris Brinze, Partner, ICR  
chris.brinze@icrhealthcare.com  
(339) 970-2843